Rapid Selection of Oseltamivir‐ and Peramivir‐Resistant Pandemic H1N1 Virus during Therapy in 2 Immunocompromised Hosts | Zendy

Matthew J. Memoli | Zendy; Rachel J. Hrabal | Zendy; Arash Hassantoufighi | Zendy; Maryna C. Eichelberger | Zendy; Jeffery K. Taubenberger | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Rapid Selection of Oseltamivir‐ and Peramivir‐Resistant Pandemic H1N1 Virus during Therapy in 2 Immunocompromised Hosts

Author(s) -

Matthew J. Memoli,

Rachel J. Hrabal,

Arash Hassantoufighi,

Maryna C. Eichelberger,

Jeffery K. Taubenberger

Publication year - 2010

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/651605

Subject(s) - oseltamivir , virology , neuraminidase , medicine , neuraminidase inhibitor , pandemic , zanamivir , virus , resistance mutation , influenza a virus , microbiology and biotechnology , drug resistance , covid-19 , biology , gene , genetics , polymerase chain reaction , disease , infectious disease (medical specialty) , reverse transcriptase

Pandemic 2009 H1N1 virus isolates containing the neuraminidase inhibitor resistance mutation H275Y have been reported. We describe rapid selection for the H275Y resistance mutation during therapy in 2 immunocompromised individuals at 9 and 14 days of therapy, as well as the first described case of clinically significant resistance to peramivir.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research